Littérature scientifique sur le sujet « Monitoring anticoagulation »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Monitoring anticoagulation ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Monitoring anticoagulation"
Smythe, Maureen A., et Anne Caffee. « Anticoagulation Monitoring ». Journal of Pharmacy Practice 17, no 5 (octobre 2004) : 317–26. http://dx.doi.org/10.1177/0897190004271775.
Texte intégralNg, Valerie L. « Anticoagulation Monitoring ». Clinics in Laboratory Medicine 29, no 2 (juin 2009) : 283–304. http://dx.doi.org/10.1016/j.cll.2009.05.003.
Texte intégralPence, Catherine, et Kimberly McErlane. « Anticoagulation Self-Monitoring ». AJN, American Journal of Nursing 105, no 10 (octobre 2005) : 62–65. http://dx.doi.org/10.1097/00000446-200510000-00036.
Texte intégralEBBERT, JON O., et ERIC G. TANGALOS. « Anticoagulation Self-Monitoring ». Internal Medicine News 39, no 20 (octobre 2006) : 44. http://dx.doi.org/10.1016/s1097-8690(06)74379-7.
Texte intégralChandler, Wayne L. « Anticoagulation Without Monitoring ». American Journal of Clinical Pathology 140, no 5 (1 novembre 2013) : 606–7. http://dx.doi.org/10.1309/ajcpe8cwkovg4agx.
Texte intégralLi Wan Po, Alain. « Self-monitoring of anticoagulation ». Lancet 379, no 9828 (mai 2012) : 1788–89. http://dx.doi.org/10.1016/s0140-6736(12)60757-0.
Texte intégralMcPherson, Mary Lynn. « Home oral anticoagulation monitoring ». Journal of Home Health Care Practice 4, no 1 (février 1992) : 63–77. http://dx.doi.org/10.1177/108482239200400110.
Texte intégralHambleton, Julie. « Home Monitoring of Anticoagulation ». Journal of Thrombosis and Thrombolysis 16, no 1/2 (août 2003) : 39–42. http://dx.doi.org/10.1023/b:thro.0000014591.32012.1f.
Texte intégralMcRae, Hannah L., Leah Militello et Majed A. Refaai. « Updates in Anticoagulation Therapy Monitoring ». Biomedicines 9, no 3 (6 mars 2021) : 262. http://dx.doi.org/10.3390/biomedicines9030262.
Texte intégralMaier, Cheryl L., et Roman M. Sniecinski. « Anticoagulation Monitoring for Perioperative Physicians ». Anesthesiology 135, no 4 (9 septembre 2021) : 738–48. http://dx.doi.org/10.1097/aln.0000000000003903.
Texte intégralThèses sur le sujet "Monitoring anticoagulation"
Coleman, B. « Requirements for a patient self monitoring service for oral anticoagulation ». Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1352827/.
Texte intégralMoussa, Mouhamed Djahoum. « Déterminants cliniques, physiopathologiques et pronostics associés aux complications liées à l’hémostase au cours des assistances circulatoires de courte durée à pompe centrifuge ». Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS055.
Texte intégralThe purpose of this dissertation is to characterize hemostasis-related complications in patients supported by peripheral VA-ECMO to improve their prevention and to optimize the antithrombotic therapeutic approaches in use. In a first study, we qualitatively and quantitatively described the composition of thrombi collected from the VA-ECMO circuits. We observed that these thrombi are mainly made of VWF, fibrin and in a lesser proportion of platelets and RBCs. Our quantitative approach also allowed us to demonstrate the presence of NETs while there was no active septic, confirming the possibility of aseptic NETosis under VA-ECMO. By hierarchical cluster analysis, we identified 2 types of thrombi, each of which may be related to a different mechanism of formation. In this study, the location of thrombi on the VA-ECMO circuit did not impact their compositions, highlighting the heterogeneity of thrombi formed within VA-ECMO and the multifactorial mechanisms that support thrombosis in this setting. In a second study, we compared the performance of surface coatings on VA-ECMO circuits to reduce thrombinoformation and its clinical consequences. Two of the most used coatings in daily practice were compared: the phosphorylcholin-based coating and the polysaccharide-albumin-based coating. We observed a higher rate of thrombotic complications in the phosphorylcholin group without any excess bleeding events or mortality in either group. In addition, compared with thrombi from phosphorylcholin-coated circuit junctions, those from polysaccharide-albumin-coated circuits were poorer in VWF. Our work suggests that the level of anticoagulation should be modulated according to the type of coating of the ECMO circuit.The aim of our third study was to identify the most relevant bleeding events that may guide clinical decision-making for more aggressive clinical management and a greater investment in research. To this end, we compared the association between 3 bleeding classifications with 28-day mortality. The ELSO definition already in use and the BARC classification classes ≥ type 2 were associated with 28-day mortality and thus retained as definitions of major bleeding. Laboratory parameters that are predictors major bleeding according to the ELSO definition were decreased fibrinogen, platelet count, and hemoglobin at cannulations. Body mass index and postcardiotomy etiology were also predictive of ELSO major bleeding. In an additional work related to the topic of the thesis, we studied two of the most used laboratory tests for the monitoring of systemic heparin during VA-ECMO, the APTT and the Anti-Xa activity, to identify the most relevant. First, we studied the relationship between these two tests and then analyzed in a second objective the impact of biological influencing factors on this relationship. Next, we determined their associations with thrombotic and hemorrhagic complications. Although linearly associated, the rate of discordance between their measurements was 39 % for an Anti-Xa reference range of 0.3 - 0.7 IU/mL. Neither APTT nor Anti-Xa was associated with thrombotic or bleeding complications. Taken together, our results highlight the heterogeneity of thrombi from peripheral VA-ECMO, the involvement of numerous causal factors that underline thrombotic and hemorrhagic complications, both not predictable by routine tests. Finally, our work underscored the need for new approaches in thrombotic or hemorrhagic complications management with targets set at an individual level considering both patient and ECMO circuit characteristics
van, Tienen EC. « Optimising warfarin management : an exploration of pharmacist-delivered models of care ». Thesis, 2012. https://eprints.utas.edu.au/16143/2/whole-excl-app-vantienen-thesis-2012.pdf.
Texte intégralFerreira, Cristina Maria Santos de Sousa. « "Modelo de acompanhamento de Doentes a tomar Anticoagulantes Orais, em âmbito de Consulta Farmacêutica. Proposta de Formação Avançada" ». Master's thesis, 2017. http://hdl.handle.net/10316/83689.
Texte intégralRacional: Os anticoagulantes orais são habitualmente utilizados na prática clinica para o tratamento e prevenção de doenças cardiovasculares, acidentes cerebrovasculares e tromboembolismo venoso. Para além dos antagonistas da vitamina K, surgiram recentemente outros anticoagulantes orais com um mecanismo de ação mais específico e aparentemente com menos limitações. Os novos anticoagulantes dispensam a monitorização analítica de rotina, mas não dispensam o acompanhamento do doente por um profissional de saúde, com o objetivo de aumentar a eficácia e segurança e maximizar a adesão á terapêutica. O farmacêutico, pelos seus conhecimentos no âmbito da farmacologia e pelo sucesso de programas de acompanhamento farmacoterapêutico, desenvolvidos em outras áreas como por exemplo a hipertensão e a diabetes, está bem posicionado para uma intervenção na gestão e acompanhamento do doente anticoagulado.Objetivo: Este trabalho pretende dar um contributo na área em 3 vertentes:1. Fazer uma revisão dos modelos existentes em outros países de acompanhamento farmacoterapêutico de doentes medicados com anticoagulantes orais.2. Criar em Portugal um método para implementar a consulta farmacêutica de acompanhamento do doente sob anticoagulação oral.3. Identificar necessidades de formação que conferem competências ao farmacêutico para fazer o acompanhamento do doente anticoagulado.Métodos: • Pesquisa na Pubmed, e em outras fontes consideradas relevantes para o tema, com o objetivo de ver o que existe publicado na área.• Os parâmetros relevantes para uma correta utilização dos anticoagulantes e acompanhamento farmacoterapêutico destes doentes são definidos com base na informação encontrada e nas características de cada fármaco.• Criação de estrutura de programa de formação para farmacêuticos.Resultados: Foi feita uma revisão dos modelos de acompanhamento de doentes anticoagulados existentes em outros países quer para os fármacos antivitamínicos K quer para os anticoagulantes orais não antagonistas da vitamina K. Foram consultadas as principais Guidelines na área e as recomendações das sociedades científicas envolvidas na utilização de anticoagulantes orais. Verificou-se que existem registos de sucesso de programas de monitorização da anticoagulação com impacto na melhoria da correta utilização dos antagonistas da vitamina K. Estes programas de acompanhamento começam a incluir os novos anticoagulantes nos seus protocolos.Com base na informação encontrada, foi criado um modelo de acompanhamento destes doentes pelo farmacêutico, com o objetivo de melhorar a eficácia e a segurança na utilização destes fármacos. Em função dos conhecimentos requeridos ao farmacêutico para que possa de forma cabal desenvolver esta atividade, é proposta uma formação estruturada na área da anticoagulação que lhe permitirá o desenvolvimento destas competências.Conclusão: Este trabalho permitiu criar um modelo de consulta farmacêutica para acompanhamento de doentes anticoagulados, para futura validação na realidade portuguesa. Espera-se assim que este modelo contribua para a melhoria do controlo dos doentes anticoagulados em Portugal, em âmbito de consulta farmacêutica.
Rationale: Oral anticoagulants are commonly used in clinical practice for the treatment and prevention of cardiovascular diseases, strokes and venous thromboembolisms. In addition to vitamin K antagonists, other oral anticoagulants have recently appeared with a more specific mechanism of action and with less apparent limitations. New anticoagulants do not require routine analytical monitoring, but do require patient follow-up by a health care professional to increase efficacy and safety and maximize adherence to therapy. The pharmacist, due to his/her expertise in pharmacology and to the success of pharmacotherapeutic monitoring programs developed in other areas such as hypertension and diabetes, is well suited for an intervention in the management and follow-up of the anticoagulated patient.Objective:This paper intends to make a contribution in the area in three aspects:1. Review existing models in other countries of pharmacotherapeutic follow-up of patients receiving oral anticoagulants.2. Create in Portugal a method to implement the pharmaceutical consultation to follow the patient under oral anticoagulation.3. Identify training needs that grant the pharmacist the necessary skills to follow the anticoagulated patient.Methods: • Research in Pubmed, and other sources considered relevant to the main topic, with the purpose of analyzing what had been published in the area. • The relevant parameters for the correct use of anticoagulants and pharmacotherapeutic follow-up of these patients were defined based on the information found and on the characteristics of each drug.• Creation of a training program structure for pharmacists. Results: A review of the anticoagulated patient follow-up models available in other countries for both anti-vitamin K drugs and non-vitamin K antagonist oral anticoagulants was undertaken. The main guidelines in the area and the recommendations of the scientific societies involved in the use of oral anticoagulants have been consulted. There have been reports of successful anticoagulation monitoring programs with impact on improving the correct use of vitamin K antagonists. These follow-up programs begin to include the new anticoagulants in their protocols.Based on the information found, a model of follow-up of these patients by the pharmacist was created with the aim of improving the efficacy and safety in the use of these drugs.Finally, based on the knowledge required of the pharmacist so that he/she can fully exert this activity, a structured training in the area of anticoagulation is proposed, which will allow him to develop these competences.Conclusion: This work allowed the creation of a pharmaceutical consultation model for the monitoring of anticoagulated patients, for future validation in the Portuguese reality.It is thus expected that this model contributes to the improvement of the control of anticoagulated patients in Portugal, in the scope of pharmaceutical consultation.
Livres sur le sujet "Monitoring anticoagulation"
Allen, Brown, Canadian Coordinating Office for Health Technology Assessment. et Canadian Agency for Drugs and Technologies in Health., dir. Devices for point-of-care monitoring of long-term oral anticoagulation therapy : Clinical and cost effectiveness. Ottawa : Canadian Coordinating Office for Health Technology Assessment, 2007.
Trouver le texte intégralWaldmann, Carl, Neil Soni et Andrew Rhodes. Haematological drugs. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199229581.003.0014.
Texte intégralProut, Jeremy, Tanya Jones et Daniel Martin. Cardiac anaesthesia. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199609956.003.0014.
Texte intégralAdam, Sheila, Sue Osborne et John Welch. Haematological problems. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199696260.003.0012.
Texte intégralBueno, Héctor, et José A. Barrabés. Non-ST-segment elevation acute coronary syndromes. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0046.
Texte intégralBueno, Héctor, et José A. Barrabés. Non-ST-segment elevation acute coronary syndromes. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0046_update_001.
Texte intégralBueno, Héctor, et José A. Barrabés. Non-ST-segment elevation acute coronary syndromes. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199687039.003.0046_update_002.
Texte intégralTorbicki, Adam, Marcin Kurzyna et Stavros Konstantinides. Pulmonary embolism. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0066.
Texte intégralTorbicki, Adam, Marcin Kurzyna et Stavros Konstantinides. Pulmonary embolism. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0066_update_001.
Texte intégralTorbicki, Adam, Marcin Kurzyna et Stavros Konstantinides. Pulmonary embolism. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0066_update_002.
Texte intégralChapitres de livres sur le sujet "Monitoring anticoagulation"
Jayaram, Kavitha. « Monitoring Anticoagulation ». Dans Transfusion Practice in Clinical Neurosciences, 417–29. Singapore : Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-0954-2_38.
Texte intégralGurbel, Paul A., et Udaya S. Tantry. « Antiplatelet Drug Resistance and Variability in Response : The Role of Antiplatelet Therapy Monitoring ». Dans Antiplatelet and Anticoagulation Therapy, 45–112. London : Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-4297-3_2.
Texte intégralSharda, Anish V., et Jeffrey I. Zwicker. « Anticoagulation Drugs : Indications, Therapeutic Monitoring, and Antidotes ». Dans Nonmalignant Hematology, 503–17. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-30352-9_44.
Texte intégralYost, Gregory W., et Steven R. Steinhubl. « Monitoring and Reversal of Anticoagulation and Antiplatelet Agents ». Dans Interventional Cardiology, 469–83. Chichester, UK : John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch49.
Texte intégralInaba, Wakiko, Akihiko Watanabe, Akitomo Koide, Sinnzo Sumita, Hiroaki Watanabe et Akiyosi Namiki. « Use of the Coagulation Monitor 512 for Reversal of Heparin-Induced Anticoagulation and the Effect of Fresh Frozen Plasma ». Dans Computing and Monitoring in Anesthesia and Intensive Care, 374–75. Tokyo : Springer Japan, 1992. http://dx.doi.org/10.1007/978-4-431-68201-1_121.
Texte intégralMcChesney, Ian. « Process Support for Continuous, Distributed, Multi-party Healthcare Processes - Applying Workflow Modelling to an Anticoagulation Monitoring Protocol ». Dans Ubiquitous Computing and Ambient Intelligence, 255–66. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-48746-5_26.
Texte intégralKinard, Theresa N. « Anticoagulation Monitoring and Reversal ». Dans Mayo Clinic Critical and Neurocritical Care Board Review, sous la direction de Eelco F. M. Wijdicks, James Y. Findlay, William D. Freeman et Ayan Sen, 353–58. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190862923.003.0055.
Texte intégralKeeling, David. « Therapeutic anticoagulation ». Dans Oxford Textbook of Medicine, 3018–22. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199204854.003.161602_update_002.
Texte intégralMazzeffi, Michael, et Ashleigh Lowery. « Anticoagulation Options ». Dans Coronary and Cardiothoracic Critical Care, 474–98. IGI Global, 2019. http://dx.doi.org/10.4018/978-1-5225-8185-7.ch022.
Texte intégralKeeling, David. « Therapeutic anticoagulation ». Dans Oxford Textbook of Medicine, sous la direction de Jeremy Dwight, 3729–34. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0376.
Texte intégralActes de conférences sur le sujet "Monitoring anticoagulation"
Seveso, M. P., A. Macagni, S. Viganò D'Angelo, C. Manotti, P. A. Bonini et A. D'Angelo. « PROTHROMBIN TIME MONITORING OF ORAL ANTICOAGULANT TREATMENT : COMPARISON OF INSTRUMENTS AND THROMBOPLASTINS ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643262.
Texte intégralTshikudi, Diane M., Michael N. Andrawes et Seemantini K. Nadkarni. « Anticoagulation and hemostasis monitoring at the bedside during cardiac surgical procedures (Conference Presentation) ». Dans Optical Diagnostics and Sensing XX : Toward Point-of-Care Diagnostics, sous la direction de Gerard L. Coté. SPIE, 2020. http://dx.doi.org/10.1117/12.2546717.
Texte intégralTshikudi, Diane M., Alexandra Wirth, Michael Andrawes et Seemantini Nadkarni. « Bedside anticoagulation monitoring during cardiac surgery with a drop of whole blood (Conference Presentation) ». Dans Advanced Biomedical and Clinical Diagnostic and Surgical Guidance Systems XVII, sous la direction de Anita Mahadevan-Jansen. SPIE, 2019. http://dx.doi.org/10.1117/12.2510608.
Texte intégralShand, R. A., K. D. Butler et J. A. Davies. « HEPARIN ANTICOAGULATION AND ITS EFFECT ON ARTERIAL THROMBUS FORMATION IN THE RABBIT ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643173.
Texte intégralTshikudi, Diane M., Alexandra G. Wirth, Michael N. Andrawes et Seemantini K. Nadkarni. « Anticoagulation and hemostasis monitoring during cardiac surgery with a drop of whole blood using a novel optical sensor ». Dans Novel Biophotonics Techniques and Applications, sous la direction de Arjen Amelink et Seemantini K. Nadkarni. SPIE, 2019. http://dx.doi.org/10.1117/12.2537923.
Texte intégralTshikudi, Diane M., Alexandra G. Wirth, Michael N. Andrawes et Seemantini K. Nadkarni. « Monitoring Anticoagulation and Hemostasis in Cardiac Surgical Patients with a Drop of Whole Blood Using a Novel Optical Sensor ». Dans Clinical and Translational Biophotonics. Washington, D.C. : OSA, 2020. http://dx.doi.org/10.1364/translational.2020.tw4b.4.
Texte intégralHulbert, J. C., J. A. Krishnan, E. Heather, N. Shapiro, S. O'Neal, A. Baucom, L. Castro et al. « A Novel Approach to Medical Monitoring During the SARS-CoV-2 Pandemic Supporting the ACTIV 4B Outpatient Anticoagulation Trial ». Dans American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1749.
Texte intégralStewart, G. J., J. W. Lachman, P. D. Alburger, M. C. Ziskin, C. M. Philips et K. Jensen. « VENODILATION AND DEVELOPMENT OF DEEP VEIN THROMBOSIS IN TOTAL HIP AND KNEE REPLACEMENT PATIENTS ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643696.
Texte intégral